


# UK Proteostasis Meeting 2026

***Two days of discussion & networking around proteostasis research***

This meeting is made possible due to sponsorship from:

THE FRANCIS CRICK INSTITUTE

**Partnership Networking Fund**

NEW ENGLAND Biolabs®

Promega

EIRNABIO ENABLING BIOINNOVATIONS

BMG LABTECH
The Microplate Reader Company

The Company of Biologists

BIOCHEMICAL SOCIETY

Stratech

Molecular Dimensions
A CALIBRE SCIENTIFIC COMPANY


Connecting people | Advancing discovery | Transforming impact
PROTEOSTASIS UK
Bringing the UK proteostasis community together
Proteostasis UK is a national research network that connects scientists to advance our understanding of proteostasis.
By connecting expertise across disciplines and biological scales we aim to accelerate discoveries that can address major societal challenges.
What We Do
• Organise meetings, workshops and networking events.
• Support collaboration through pump-priming grants
• Promote knowledge and expertise sharing
• Support ECR training and career development.
• Share news, updates, and opportunities across the proteostasis community through our monthly newsletter.
Scan to join the network
Free, simple and quick to sign up
Biotechnology and Biological Sciences Research Council
Find out more at:
https://proteostasisuk.co.uk/

EIRNABio
ENABLING BIOINNOVATIONS

# Unlock the secrets of translation with EIRNABio

GLOBAL LEADERS IN THE FIELD OF TRANSLATOMICS

## Measure translation directly from sample to biological insight

EIRNABio combines scalable experimental platforms with intuitive analysis tools so researchers can explore translation efficiency, ribosome occupancy, pausing, readthrough and hidden translated regions with confidence.

- **High-throughput Ribo-seq**

Ribo96 enables larger, reproducible studies in a 96-well format.

- **No command line required**

Browser-based EIRNABio Connect makes analysis accessible and shareable.

- **Beyond annotated coding**

Translon Explorer helps uncover uORFs, altORFs and microprotein candidates.

## Our Translatomics Services

### Ribosome Profiling (Ribo-seq)

Including 96-well format and ultra-low input workflows for precious samples.

### Disome Profiling (Disome-seq)

Provides insights into ribosome collisions and ribosome pausing biology.

### Polysome Profiling (Polysome-seq)

Quantifies ribosome loading at isoform level across experimental conditions.

### tRNA-seq

Assesses tRNA abundance and modifications linked to translation control.

www.eirnabio.com info@eirnabio.com

EIRNABio
ENABLING BIOINNOVATIONS

# From High-Throughput Ribo-Seq to Actionable Translational Biology

Ribo96 creates the experimental design space; EIRNABio Connect and Translon Explorer turn scaled datasets into interpretable outputs.


## Why Ribo96 helps larger studies

- **Scale:** Profile more conditions, doses, time points and replicates.
- **Automation:** Improve reproducibility and reduce hands-on variability.
- **Low input:** Unlock Ribo-seq for precious samples with RNA in the nanogram range.

## Why use EIRNABio-Connect

- Interactive plotting and dynamic visualisation.
- Reproducible workflows and standardised reporting.
- Seamless sharing for collaborative interpretation.

## Applications: Turn scaled ribosome profiling into biological decisions

- Drug mechanism of action: Ribosome pausing, TE shifts and pathway-level responses.
- UORF regulation: Condition-specific upstream ORF usage and repression/activation.
- Protein expression optimisation: Codon-optimise constructs and evaluate suppressor tRNA etticacy.
- Disease-specific signatures: Translation-focused phenotypes beyond RNA abundance
- Codon occupancy and readthrough: Codon-level effects, stop-codon readthrough and tRNA-related biology.
- Hidden translation discovery: Expand the translatome and generate new hypotheses.

www.eirnabio.com info@eirnabio.com

UK PROTEOSTASIS MEETING 2026

# Bioluminescent tools for protein stability, degradation & target engagement

**20–21 July 2026** · The Francis Crick Institute, London

Promega

## ABOUT PROMEGA

**Founded in 1978 and headquartered in Madison, Wisconsin, Promega develops reagents, assays and automation for the life sciences.** The portfolio spans protein analysis and expression, protein degradation, cell-based and biochemical assays, drug discovery, genomics and nucleic acid analysis, and genetic identity underpinned by the bioluminescent detection chemistries Promega is known for.

## FOR PROTEOSTASIS RESEARCH

### HiBiT

Antibody-free quantification of endogenous protein levels and degradation kinetics. A standard readout for targeted protein degradation, PROTAC and protein-stability studies.

### NanoBRET® Target Engagement

Live-cell measurement of compound–target binding and occupancy, from biochemical characterisation through to cellular potency.

### TarSeer™ BRETSA™ EARLY ACCESS

Tracer- and antibody-free target engagement in live cells, measuring ligand-induced changes in protein thermal stability. Suited to challenging targets across hit validation and lead optimisation.

### NanoLuc® luminescent chemistry

The bright, stable luciferase behind these tools, including the thermostable StabiLuc™ used in BRETSA.

**Ahmed Sidali, PhD**
Key Account Manager · Promega UK
07741 017449 · Ahmed.sidali@promega.com

# Schedule

## Day 1: Monday July 20th

09:30 - 10:30 am – Arrival/coffee/registration

10:30 - 10:45 am – Welcome and important information for attendees

**Keynote Talk**

10:45 - 11:20 : Laurence Pearl (Institute of Cancer Research / University of Sussex)

*"Protein kinase regulation by the HSP90 molecular chaperone system"*

11:20 – 12:00: PI Flash talks 1

12:00 – 12:40: Flash talks for posters 1

12:40 - 14:10: Lunch and posters 1

**Research Talks 1**

14:10 – 14:25: Daniel Maddison (University of Cambridge)

*“BiP mediated disaggregation of amyloid-beta throughout the secretory pathway”*

14:25 – 14:40: Claudia De Miguel (MRC LMB)

*“Termination of the Integrated Stress Response”*

14:40 – 14:55: Max Thompson (Babraham Institute)

*“Clearance of age-associated aggregates by late-life DAF-2 inhibition”*

14:55 – 15:10: Francesca van Tartwijk (British Antarctic Survey / University of Cambridge)

*“Organelle morphology reflects proteostatic stress in the Antarctic spiny plunderfish Harpagifer antarcticus”*

15:10 – 15:50: PI Flash Talks 2

15:50 - 16:20: Coffee break

**Research Talks 2**

16:20 – 16:35: Virginia De Cesare (MRC PPU / University of Dundee)

*“E2s that behave differently: UBE2Q1 non-canonical ubiquitylation machinery”*

16:35 – 16:50: Abid Javed (Francis Crick Institute)

*“Dissecting the Trigger factor-nascent chain engagement on the ribosome using cryo-EM”*

16:50 – 17:05: Sam Taylor (University College London)

*“An ER-to-cytosolic stress response promotes proteostasis and reproductive health”*

17:05 - 17:50: Proteostasis Consortium networking session

*“Proteostasis UK Network: Bringing the UK Proteostasis Community Together”*

17:50 - 18:30: Flash talks for posters 2

18:30 - 20:00: Dinner and posters 2

20:00 - 21:00: Drinks

## Day 2: Tuesday July 21st

08:30 - 9:30 am: Arrival and coffee

**Keynote talk**

09:30 - 10:05: Sylvie Urbe (University of Liverpool)

*“Mechanisms of Mitophagy: How Ubiquitylation and Mitochondrial Import Govern Quality Control Pathways”*

**Research Talks 3**

10:05 – 10:20: Nerea Blanes Ruiz (King’s College London)

*“p62 modules astrocytic handling of pathological tau under inflammatory conditions”*

10:20 – 10:35: Yassin Ben Khoud (Imperial College London)

*“Structure of ER chaperone complex GRP170-ATP-BiP suggests a new model for substrate engagement”*

10:35 – 10:50: Wen Kin Lim (Babraham Institute)

*“Impact of RNA oxidation on ribosome dysfunction and proteostasis with age”*

10:50 – 11:05: Tamara Sijacki (The Francis Crick Institute)

*“Investigating the in-situ architecture of bacterial degradation complexes”*

11:05 – 11:30: Coffee break

11:30 - 11:45: Jasmeen Oberoi (University of Sussex)

*“The Proteostasis UK ECR Network”*

11:45 - 12:25: Flash Talks for posters 3

12:25 - 14:00: Lunch and posters 3

14:00 - 14:45: Proteostasis UK industry panel session

*“An Industry Perspective on Proteostasis Research: Building Successful Academia–Industry Partnerships”*

14:45 – 15:15 – Coffee break

**Research Talks 4**

15:15 – 15:30: Julie Maupin (University of Florida)

*“Archaeal post-translational systems and proteostasis networks”*

15:30 – 15:45: Nicholas Marzano (University of Oxford)

*“Escaping the HSP70 trap: how HSP90 restores protein folding”*

15:45 – 16:00: Marian Peteri (University of Dundee)

*“Genome-wide CRISPR inhibition screen reveals UPR-mediated suppression of ER-phagy”*

16:00 – 16:15: Girish Ram Mali (University of Oxford)

*“Ciliophagy promotes motile cilia recycling under stress”*

16:15 – 16:30: Renren Chen (MRC LMB)

*“Pathological TDP-43 filaments accumulate at synapses and cause synaptic dysfunction”*

16:30 – 16:45: Tom McGirr (Queen’s University Belfast)

*“4EHP-mediated translational repression maintains cell survival following ionizing radiation”*

16:45 - 18:00 – wrap-up and home time with extended networking

## Industry panel members

**Kuan-Chuan (Eric) Pao | Outrun Therapeutics | Translational principal scientist and Scientific Co-Founder**

**LinkedIn: www.linkedin.com/in/kuan-chuan-pao-43509ab6/**
**Website: https://outruntx.com/**

**Speaker Biography**
Kuan-Chuan (Eric) Pao is a translational principal scientist and Scientific Co-Founder of Outrun Therapeutics, a venture-backed biotech developing first-in-class small-molecule therapies for cancer. He leads the company's discovery biology, overseeing programmes from target identification through screening and in vivo proof-of-concept to development-candidate selection across oncology and neurodegeneration diseases. His work spans functional-genomic target discovery, chemical biology and small-molecule drug discovery (HTS, covalent and DEL screening), with a focus on protein quality control and the ubiquitin system. Before co-founding Outrun, Eric trained at UC Berkeley with Prof. Michael Rapé and completed his PhD in Chemical Biology at the MRC-PPU, University of Dundee, where he published first-author papers in Nature and Nature Chemical Biology and developed the patented technology that became Outrun's platform. He also brings clinical and commercial perspective from his time as a Medical Science Liaison at Roche, working on precision-oncology companion diagnostics. Eric holds a PhD from the University of Dundee.

**Company Description**
Outrun Therapeutics is a Dundee-based, venture-backed biotechnology company discovering first-in-class small-molecule therapies for cancer. Built on patented ubiquitin and E3-ligase technology spun out of the University of Dundee, Outrun's programmes target protein quality-control vulnerabilities in solid tumours, with a pipeline spanning oncology, neuron degeneration and autoimmune diseases. Outrun operates a lean, globally externalised model, coordinating discovery and translational work across multiple CRO partners.

---

**Benedict CS Cross | Stick Therapeutics | Founder & CEO**

**LinkedIn: www.linkedin.com/in/benedict-cs-cross**
**Website: https://www.sticktx.co.uk/**

**Speaker Biography**
Ben is co-founder & CEO of Stick Therapeutics and a business leader and a serial biotech platform builder (PhoreMost Ltd, Horizon Discovery). As a pioneer in the use of synthetic biology in drug discovery, he has authored over 30 peer-reviewed studies and patents working at the intersection of biology, drug discovery and data science.

**Company Description**
Stick has established a blockbuster breakthrough to enable the routine discovery of molecular glue drugs. Using a proprietary deep biology engine to enrich computational hit ID, Stick have built an internal pipeline of unprecedented discovery programmes and are poised to rewrite the rules for this remarkable medicine modality.

---

**Urvashi Thacker | Syngenta | Biochemistry Lead**

**LinkedIn: www.linkedin.com/in/urvashi-thacker-b191119**
**Website https://www.syngenta.co.uk**

**Speaker Biography**
Dr. Urvashi Thacker is Biochemistry Lead at Syngenta, with over 18 years of scientific and leadership experience in the UK. I hold a PhD in Biotechnology from India and have extensive expertise in molecular target identification using chemical biology approaches. I lead multidisciplinary research projects and manage a team of scientists developing biochemical and binding assays to support innovative crop protection research. I am passionate about science and curious about proteostasis across kingdoms, with a specific interest in species relevant to crop protection. As a member of the Proteostasis UK steering committee, I look forward to collaborating with other experts and bringing an industry perspective to the network to support the committee's goals and the wider scientific community.

**Company Description**
Syngenta is a global leader in agricultural innovation, with a presence in more than 90 countries, developing technologies that help farmers grow safe, nutritious food while protecting the planet. Jealott's Hill is Syngenta's largest crop protection research and development site worldwide and the UK's largest commercial agricultural technology research campus. Syngenta's products include crop protection active ingredients, biological solutions, seeds and digital tools that improve farm productivity while reducing environmental impact. These solutions are used across a wide range of crops, including cereals, fruit, vegetables and speciality crops. Customers include farmers and growers across the world.

---

**James Robinson| AstraZeneca |Lead investigator on the AstraZeneca/Crick/Imperial Prosperity Partnership**

**Website https://www.astrazeneca.co.uk/**

**Speaker Biography**
James Robinson studied for his PhD at University College London, investigating mechanisms of GPCR signaling and regulation, before undertaking a postdoc at The Scripps Research Institute, focused on mechanistic pharmacology of the Orexin-1 Receptor. He joined AstraZeneca's Cellular Assay Development team in 2015 and was appointed as a Team Leader in the Mechanistic Biology and Profiling department in 2019, where he is now a Director of Pharmacology. James' group delivers high-quality profiling data and deep mechanistic understanding to drive a variety of early drug discovery projects. Since 2023, James has also been a lead investigator on the AstraZeneca/Crick/Imperial Prosperity Partnership that aims to develop a rulebook for the discovery of molecular glue degraders for intractable targets.

---

**Fiona Menzies| Eli Lily |Associate Vice President at Eli Lily and Company**

**Company Description**
Eli Lilly is a research-driven pharmaceutical company focused on developing innovative medicines for some of the world's most significant health challenges. Its research portfolio spans cardiometabolic diseases, including obesity, diabetes, and related metabolic disorders; neuroscience, with major programmes in Alzheimer's disease and other neurodegenerative conditions; oncology, where it develops targeted therapies for a range of cancers; and immunology, addressing autoimmune and inflammatory diseases. The company combines expertise in biologics, small molecules, and next-generation therapeutic approaches to translate scientific discoveries into treatments that improve patient outcomes. In recent years, Lilly has become particularly recognised for its leadership in obesity and diabetes research while continuing to invest heavily in cancer and neuroscience drug development.

## Travel and accommodation

We strongly recommend booking early. When planning your journey, please allow additional time for travel, particularly during peak hours

The Francis Crick Institute, *1 Midland Road, London NW1 1AT, UK*, is centrally located next to King's Cross St Pancras, one of London's main transport hubs with easy access by train, tube and bus.

***Getting there:*** Check the Francis Crick Institute website for travelling information https://www.crick.ac.uk/about-us/visit-us and plan your route with the Transport for London journey planner.

***Accommodation:*** Many hotels are located just a few minutes' walk from King's Cross and St Pancras stations, including hotel chains such as Premier Inn, Holiday Inn or Travelodge, alongside independent hotels and guesthouses.